Demecan
Demecan is an independent German medical cannabis producer founded in 2017, vertically integrating EU-GMP cultivation, pharmaceutical extraction, and direct-to-pharmacy distribution from its Ebersbach facility near Dresden to German pharmacies and patients.
- Company typePrivate
- Founded2017
- HeadquartersEbersbach, Germany
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Demecan does
Demecan is an independent German medical cannabis company founded in 2017 and headquartered in Ebersbach near Dresden. It operates the largest indoor medical cannabis production facility in Europe at the "Cannabis Campus," a former slaughterhouse acquired from Wayland in 2020 and progressively converted into EU-GMP-compliant cultivation and processing. The company is vertically integrated across the full value chain: cultivation under GACP standards, pharmaceutical-grade processing including proprietary Live Rosin cold-water extraction and solvent-free CO2 extraction, and direct distribution to German pharmacies via its own online shop (Fachbereich) and the herbery.de pharmacy platform, supported by a Frankfurt-based field sales team.
Its product portfolio comprises two main medical cannabis flower lines (CORE and CRAFT cultivars such as SKYGLOW, MAGISTER, SAXONIA, ICC, JM7, ECHO, and SUNSHINE PURE), the Oktonia extract line with six THC/CBD ratio variants, the FE 800 No. 1 Live Rosin extract, and the One concentrate 850 CO2 extract. Supporting digital services include the Patientenausweis digital patient ID card, an Apothekenfinder pharmacy locator, and the herbery.de SaaS pharmacy platform run by subsidiary Theranova Digital Solutions GmbH. Demecan sells exclusively to German pharmacies, which in turn dispense to patients on physician prescription, with statutory health insurance reimbursement available under certain conditions.
Commercially, Demecan generates revenue through wholesale flower and extract sales, imports from international producers to broaden its range, and laboratory/processing services to third parties. Pricing is not publicly disclosed and is shaped by pharmacy reimbursement mechanics. The company has secured two major regulatory milestones — the 2019 BfArM state cultivation contract as the only independent German producer, and the July 2024 MedCanG cultivation license as the first German recipient, which removed prior production caps — and has raised roughly €15M in 2022 and a high-seven-figure round at a ~€100M valuation in 2024 led by U.S.-based Trog Hawley Capital.
Demecan firmographics
Firmographics- Name
- Demecan
- Legal name
- DEMECAN Holding GmbH
- Website
- https://demecan.de
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Demecan is an independent German medical cannabis producer founded in 2017, vertically integrating EU-GMP cultivation, pharmaceutical extraction, and direct-to-pharmacy distribution from its Ebersbach facility near Dresden to German pharmacies and patients.
- Ownership category
- akta.pro rank
Demecan industry classification
Industry- Product category
- Medical Cannabis
- NAICS
- Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)
- akta.pro primary industry
- Medical Cannabis Dispensaries (CRANAFAB)
- akta.pro secondary industries
- Medical Cannabis Delivery & Online Ordering (CRANAGAG), Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail) (CRANAFAG)
Keywords
Where Demecan is headquartered
LocationHeadquarters
- HQ city
- Ebersbach
- HQ country
- Germany
- HQ region
- Europe
Offices5 records
Markets served
Demecan business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Cannabis Flower Sales: Sale of medical cannabis flower products to pharmacies in Germany. Products include various strains with different THC/CBD profiles and terpenes.
- Medical Cannabis Extracts: Production and sale of cannabis extracts including Oktonia product line with various THC/CBD ratios for different therapeutic applications.
- Medical Cannabis Import: Import of medical cannabis from producers worldwide to expand product range and meet high-quality standards while complementing domestic production.
- Wholesale Distribution: Wholesale operations working with cannabis producers worldwide to ensure supply of medical cannabis to patients in Germany.
- Laboratory and Processing Services: Laboratory and processing services related to medical cannabis offered to third parties, including processing of cannabis flowers at the Ebersbach facility.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
Demecan product offering
Product offeringCore offering
Demecan cultivates, manufactures, and distributes medical-grade cannabis flowers and extracts under EU-GMP pharmaceutical standards at its facility near Dresden, selling exclusively to German pharmacies through its Fachbereich online shop, field sales force, and herbery.de platform. The company operates the only fully independent, vertically integrated medical cannabis value chain in Germany — from cultivation through pharmaceutical processing to pharmacy delivery — with an annual production capacity of approximately 2 tons under its MedCanG cultivation license.
Product overview
DEMECAN is an independent German medical cannabis company covering the entire value chain from cultivation to pharmacy delivery. The product portfolio consists of medical cannabis flowers (CORE and CRAFT product lines with various cultivars and terpene profiles) and cannabis extracts (DEMECAN Oktonia product line including Typ1 extracts with calming effect and Typ2 extracts with stimulating effect, plus DEMECAN FE 800 and DEMECAN One concentrate). Supporting services include a digital patient ID card (DEMECAN Patientenausweis), an online pharmacy platform (herbery.de), and a pharmacy finder tool. The company operates from its production facility in Ebersbach near Dresden and sells exclusively to pharmacies.
Differentiator
Problem solved
Functional benefit
Brands
- Herbery.de: Online pharmacy platform for medical cannabis distribution
- DEMECAN Wallet App
- DEMECAN Patientenausweis
- Cannabis Campus
Products and services
- DEMECAN CORE Medical Cannabis Flowers
Quantifiable outcome
- ~2 tons annual cannabis yield capacity
- +2 more outcomes
Companies that use Demecan
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Demecan technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Demecan partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Federal Institute for Drugs and Medical Devices (BfArM)coreGovernment agency that awarded DEMECAN the state contract in May 2019 as the only independent German company to cultivate medical cannabis in Germany. Continued regulatory oversight for medical cannabis production.
- Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC)minorFederal Association of Pharmaceutical Cannabinoid Companies - DEMECAN is a member, contributing to industry advocacy and standards development.
- Bundesverband der Cannabiswirtschaft (BvCW)minorFederal Association of the Cannabis Industry - DEMECAN is a member, contributing to industry advocacy.
- Association of Pharmacies Supplying Cannabis (VCA e.V.)minorDEMECAN is a supporting member of the Association of Pharmacies Supplying Cannabis.
- DentonsminorGlobal law firm prepared a legal opinion for DEMECAN for a scientific cannabis pilot project in Germany, addressing EU and international law compliance for cannabis legalization.
- MXP GmbHminorLogistics partner involved in order fulfillment for pharmacy product distribution.
- trans-o-flex Express GmbH & Co. KGaAminorShipping partner for product delivery to pharmacies in Germany, located in Weinheim.
Scale indicators12 records
Recent moves8 records
Expansion highlights6 records
Demecan competitors and assessment
Company assessmentBroad incumbents
- Organigram Holdings: Canadian licensed producer that has built European distribution including German medical cannabis. Comparable as another established import-source producer competing for shelf space and physician adoption in Germany.
- Canopy Growth: Global cannabis incumbent with prior German medical cannabis presence. Comparable as a large, multi-jurisdiction EU-GMP-certified producer whose import volumes compete with DEMECAN's domestic product in German pharmacy channels.
- Curaleaf International (formerly EMMAC Life Sciences): European medical cannabis operator with EU-GMP cultivation and distribution across multiple EU markets including Germany. Comparable as a multi-country producer/distributor targeting the same German pharmacy network.
- Aurora Cannabis: Canadian-licensed global cannabis producer with significant European footprint including German operations. Comparable as a multi-jurisdiction producer competing with DEMECAN for the same German pharmacy/patient demand with imports.
- Tilray Brands: Large global cannabis operator with established EU-GMP-certified production in Portugal/Canada supplying the German medical market. Comparable as an international low-cost producer supplying German pharmacies via imports that compete directly with DEMECAN's domestic flower.
Direct peers
- Sanity Group: Berlin-based German medical cannabis company also founded post-2017 to serve the domestic medical and emerging legal market. Directly comparable as a German-headquartered, vertically oriented cannabis operator with cultivation/processing ambitions and pharmacy-channel distribution.
- Cantourage: Berlin-based medical cannabis company distributing imported cannabis flower and extracts to German pharmacies. Comparable as a direct Germany-focused medical cannabis distributor with a pharmacy-led GTM motion similar to DEMECAN's Fachbereich shop.
- Cansativa: German B2B cannabis platform operating a pharmacy-facing ordering and distribution marketplace for medical cannabis. Comparable because it competes for the same German pharmacy relationships and serves the same prescriber/patient flow.
Emerging players
- Bodhi+: Emerging European cannabis operator with German-market activity. Comparable as a smaller, niche European producer/distributor targeting the same medical cannabis pharmacy channel as DEMECAN.
- enua: Cologne-based German medical cannabis startup focused on pharmacy distribution. Comparable as a smaller Germany-only competitor operating in the same pharmacy-prescriber ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Demecan social profiles
Digital presenceDemecan compliance and trust
Trust signalCompliance3 records
Demecan financial estimates
Financial estimateRevenue estimate
Valuation estimate
Demecan leadership team
Management profileNumber of profiles
Profiles8 records
Demecan subsidiaries and ownership
Company hierarchySubsidiaries4 records
Demecan funding detail
Funding detailFunding overview
Funding rounds6 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Demecan M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Demecan
What does Demecan do?
Demecan cultivates, manufactures, and distributes medical-grade cannabis flowers and extracts under EU-GMP pharmaceutical standards at its facility near Dresden, selling exclusively to German pharmacies through its Fachbereich online shop, field sales force, and herbery.de platform. The company operates the only fully independent, vertically integrated medical cannabis value chain in Germany — from cultivation through pharmaceutical processing to pharmacy delivery — with an annual production capacity of approximately 2 tons under its MedCanG cultivation license.
Is Demecan a public or private company?
Demecan is a private company. It is classified as venture growth investor backed and is currently operating.
When was Demecan founded?
Demecan was founded in 2017. It employs 51 to 100 people.
Where is Demecan based?
Demecan is headquartered in Ebersbach, Germany, in the Europe region.
How does Demecan make money?
Five revenue lines are on record. Medical Cannabis Flower Sales are the primary driver. The others are medical Cannabis Extracts, medical Cannabis Import, wholesale Distribution and laboratory and Processing Services.
Who are Demecan's main competitors?
Broad incumbents on record are Organigram Holdings, Canopy Growth, Curaleaf International (formerly EMMAC Life Sciences), Aurora Cannabis and Tilray Brands. Direct peers are Sanity Group, Cantourage and Cansativa. Emerging players are Bodhi+ and enua.
Does Demecan have an API?
No public API is recorded for Demecan.
What industry is Demecan in?
Demecan's product category is Medical Cannabis. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of CRANAGAG, Medical Cannabis Delivery & Online Ordering. Its NAICS code is 325411 and its SIC code is 2833.